Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
To the Editor: Despite recent advances in therapy, pulmonary arterial hypertension (PAH), characterized by occlusive vasculopathy of the pulmonary arteries, remains a progressive disease without a cure (1–3). Although currently approved PAH medications have not demonstrated antiremodeling properties in humans, novel antiproliferative strategies have shown some benefits and also raised safety concerns (4–6); for example, none target a genetic predisposition of PAH: dysfunctional bone morphogenetic protein receptor 2 (BMPR2) signaling. Loss-of-function mutations in BMPR2 in patients with familial and idiopathic PAH (7–9) are associated with increased pulmonary vasculopathy (10). Furthermore, reduced BMPR2 expression is observed even in patients without a mutation, reinforcing the importance of decreased BMPR2 in PAH (11). In a high-throughput screen of 3,600 drugs approved by the U.S. Food and Drug Administration, we identified low-dose FK506 (tacrolimus) as a potent BMPR2 activator that reversed experimental PAH (12). We therefore hypothesized that low-dose FK506 would be beneficial in patients with PAH by increasing BMPR2 signaling. On the basis of these findings, we initiated a randomized, double-blind, placebo-controlled phase IIa trial (FK506 [Tacrolimus] in Pulmonary Arterial Hypertension [TransformPAH]) to evaluate the safety and tolerability of FK506 in stable patients with PAH. Here, we report our clinical experience with compassionate use of low-dose FK506 in three patients with end-stage PAH who did not qualify for our trial because of the severity of their illness (patient details are provided in the online supplement). We assessed traditional clinical parameters, New York Heart Association (NYHA) functional class, 6-minute-walk distance, serologic biomarkers, and hospital admissions, as well as protocolized cardiac magnetic resonance imaging assessed by blinded readers (13, 14). All patients continued receiving stable doses of PAH medication and diuretics throughout the 12-month period. The TransformPAH clinical trial was registered with www.clinicaltrials.gov (NCT 01647945). Patient 1 Patient 1 is a 36-year-old historically athletic woman, NYHA-IV, with rapidly progressive idiopathic PAH requiring rapid up-titration of epoprostenol and the addition of sildenafil and ambrisentan for recurrent hospitalizations for right ventricular (RV) failure (Figure 1). Despite aggressive treatment, she still reported NYHA-III/IV symptoms, an elevated N-terminal-pro-B type natriuretic peptide, and a Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk score of 11, stratifying her as high risk with a potential 1-year mortality risk of 15–30% (3, 15). She was listed for lung transplantation. At that time, she was offered compassionate treatment with FK506 (goal trough blood level, 1.5–2.5 ng/ml). Figure 1. Timeline of symptoms, clinical parameters, events, and therapies for patients 1–3 before and after initiation of FK506. Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk score, %1-year survival: score 1–7 = 95–100% ... Within 1 month of FK506 initiation, she reported substantial improvement in symptoms (Figure 2). Within 2 months, she was placed on hold for transplantation by the lung transplant team. After 3 months, her 6-minute-walk distance improved by 100 m, her N-terminal-pro-B type natriuretic peptide decreased more than 50%, and she reported NYHA-I symptoms (Figure 1; see Figure E1A in the online supplement). During the 12-month period, cardiac magnetic resonance imaging showed a stable RV ejection fraction, RV end-diastolic volume index, and cardiac index (Figure E1B). Her REVEAL risk score decreased to 3 (range, 3–6), placing her in the low-risk category (Figure 1). Although the 12 months before FK506 were characterized by three hospitalizations for RV failure, the subsequent 12 months were free of any PAH-associated hospitalizations (Figure 1). At the time of this submission, the patient is 27 months from the initiation of FK506, continues to report NYHA-II symptoms, and has been free from hospitalization or clinical deterioration. Figure 2. Biomarkers for patients 1–3 before and after initiation of FK506. (A) Bone morphogenetic protein receptor 2 (BMPR2) messenger RNA (mRNA)/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in peripheral blood mononuclear cells (PBMCs) of healthy ... Patient 2 Patient 2 is a 50-year-old woman with end-stage systemic sclerosis–associated PAH receiving intravenous treprostinil, sildenafil, and ambrisentan, as well as an intravenous dopamine infusion for end-stage RV failure and hypotension. The patient continued to report NYHA-III/IV symptoms and had an elevated N-terminal-pro-B type natriuretic peptide (range, 4,926–15,161 pg/ml) and four hospitalizations for progressive RV failure and palliative paracenteses (Figure 1). Given the lack of further therapeutic option
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
van de Veerdonk, M. C., Kind, T., Marcus, J. T., Mauritz, G.-J., Heymans, M. W., Bogaard, H.-J., Boonstra, A., Marques, K. M. J., Westerhof, N., & Vonk-Noordegraaf, A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.068 · Cited by 846
Cited by
TGF-β Signaling in Control of Cardiovascular Function
Goumans, M.-J., & ten Dijke, P. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022210 · Cited by 360
Colucci, S., Pagani, A., Pettinato, M., Artuso, I., Nai, A., Camaschella, C., & Silvestri, L. (2017) · Blood · doi:10.1182/blood-2017-04-780692 · Cited by 62
“More recently, a pilot study with the same drug ameliorated the clinical condition of 3 patients with end-stage pulmonary hypertension.(53) Considering that, in our hands, tacrolimus upregulates hepcidin in Hjv hepatocytes and that in vivo Hjv is dispensable for hepcidin upregulation by iron,(54) tacrolimus-like drugs…”
BackgroundTampe, B., Tampe, D., Nyamsuren, G., Klöpper, F., Rapp, G., Kauffels, A., Lorf, T., Zeisberg, E. M., Müller, G. A., Kalluri, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci89632 · Cited by 24
“gov identifier NCT01647945) and shown promise in pulmonary arterial hypertension patients to induce protective BMP signaling responses (52).”
Metadata
- Authors
- Spiekerkoetter, E., Sung, Y. K., Sudheendra, D., Bill, M., Aldred, M. A., van de Veerdonk, M. C., Noordegraaf, A. V., Long-Boyle, J., Dash, R., Yang, P. C., Lawrie, A., Swift, A. J., Rabinovitch, M., & Zamanian, R. T.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07-15
- Volume
- 192
- Issue
- 2
- Pages
- 254-257
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W1811208101
- Cited by
- 113
- References
- 1
- FWCI
- 12.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. https://app.cochat.ai/papers/10.1164/rccm.201411-2061le
- The paper
- Spiekerkoetter, E., Sung, Y. K., Sudheendra, D., Bill, M., Aldred, M. A., van de Veerdonk, M. C., Noordegraaf, A. V., Long-Boyle, J., Dash, R., Yang, P. C., Lawrie, A., Swift, A. J., Rabinovitch, M., & Zamanian, R. T. (2015). Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201411-2061le
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.